Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
3 clinical-grade skincare creams you really shouldn’t buy online 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Add as a preferred source on Google
Cancer is one of the leading causes of death in terms of medical issues in the world, affecting over 14 million patients on earth. The number of cancer patients is expected to grow by 2030, reaching over 21.7 million in the process. During that time, an estimated 13 million will have died due to their sickness or complications related to them. In response to the growing medical threat, an alliance comprised of major cancer organizations was formed to essentially create a cancer vaccine.
A significant number of cancer types are treatable, but due to lifestyle choices, work, stress factors, and even environmental influences, the health issue can still persist. In order to find a better way of addressing cancer, the Parker Institute for Cancer Immunotherapy partnered with the Cancer Research Institute and other organizations, Futurism reports.
The Parker Institute for Cancer Immunotherapy is the project of Sean Parker, the tech billionaire. Right now, the alliance counts 30 major organizations as members, including known universities and non-profit groups.
The focus of the alliance’s efforts will be research into neoantigens, which are considered genetic markers for specific cancer tumors. This makes them perfect for quickly detecting cancer within specific individuals, thus making early diagnosis much easier.
More than that, by crunching numbers via algorithms that analyze both DNA and RNA sequences, the presence of neoantigens is easier to detect. Once that happens, it would then be simpler for scientists to come up with a way to make it more visible to the immune system, thus destroying it before tumors appear.
Parker is particularly committed to ensuring that the alliance and its efforts bear fruit at some point, already having donated over $250 million to cancer research, TechCrunch reports. According to him, creating the alliance and directing their efforts to detect tumor markers is exactly what he wanted to achieve when he started his institute.
